Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 1
1997 2
1998 6
1999 4
2000 7
2001 17
2002 13
2003 13
2004 18
2005 21
2006 24
2007 29
2008 20
2009 21
2010 12
2011 16
2012 14
2013 8
2014 10
2015 7
2016 5
2017 9
2018 9
2019 11
2020 12
2021 9
2022 10
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Results by year

Filters applied: . Clear all
Page 1
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Mühlbauer V, et al. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2. Cochrane Database Syst Rev. 2021. PMID: 34918337 Free PMC article. Review.
Some trials have yielded negative results and effectiveness may be outweighed by harms. OBJECTIVES: To assess the efficacy and safety of antipsychotics for the treatment of agitation and psychosis in people with Alzheimer's disease and vascular dementi …
Some trials have yielded negative results and effectiveness may be outweighed by harms. OBJECTIVES: To assess the efficacy and safety of …
Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
Varadharajan A, Davis AD, Ghosh A, Jagtap T, Xavier A, Menon AJ, Roy D, Gandhi S, Gregor T. Varadharajan A, et al. J Neurosci Rural Pract. 2023 Oct-Dec;14(4):566-573. doi: 10.25259/JNRP_356_2023. Epub 2023 Oct 7. J Neurosci Rural Pract. 2023. PMID: 38059250 Free PMC article. Review.
The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to improve the quality of life of patients and caregivers. Alzheimer's disease (AD), a neurodegenerative disease, is the mos …
The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to improve t …
Pharmacological Management of Dementia with Lewy Bodies.
Hershey LA, Coleman-Jackson R. Hershey LA, et al. Drugs Aging. 2019 Apr;36(4):309-319. doi: 10.1007/s40266-018-00636-7. Drugs Aging. 2019. PMID: 30680679 Free PMC article. Review.
DLB is the third most common of all the neurodegenerative diseases behind both Alzheimer's disease and Parkinson's disease (PD). The median age of onset for DLB (76.3 years) is younger than that seen in PD dementia (81.4 years). New pathological studie …
DLB is the third most common of all the neurodegenerative diseases behind both Alzheimer's disease and Parkinson's d …
Psychosis in Alzheimer's Disease.
Ballard C, Kales HC, Lyketsos C, Aarsland D, Creese B, Mills R, Williams H, Sweet RA. Ballard C, et al. Curr Neurol Neurosci Rep. 2020 Oct 13;20(12):57. doi: 10.1007/s11910-020-01074-y. Curr Neurol Neurosci Rep. 2020. PMID: 33048274 Free PMC article. Review.
PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer's disease (AD). RECENT FINDINGS: Psychosis in Alzheimer's disease (AD) has an incidence of ~ 10% …
PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzhei …
Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.
Calsolaro V, Femminella GD, Rogani S, Esposito S, Franchi R, Okoye C, Rengo G, Monzani F. Calsolaro V, et al. Pharmaceuticals (Basel). 2021 Mar 9;14(3):246. doi: 10.3390/ph14030246. Pharmaceuticals (Basel). 2021. PMID: 33803277 Free PMC article. Review.
Dementia affects about 47 million people worldwide, number expected to exponentially increase within 30 years. Alzheimer's disease (AD) is the most common dementia type, accounting on its own for almost 70% of all dementia cases. ...In this literature review …
Dementia affects about 47 million people worldwide, number expected to exponentially increase within 30 years. Alzheimer's …
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
Fischer CE, Namasivayam A, Crawford-Holland L, Hakobyan N, Schweizer TA, Munoz DG, Pollock BG. Fischer CE, et al. Psychiatr Clin North Am. 2022 Dec;45(4):691-705. doi: 10.1016/j.psc.2022.07.001. Epub 2022 Oct 14. Psychiatr Clin North Am. 2022. PMID: 36396273 Review.
The evidence base for emerging therapies including citalopram and pimavanserin in relation to conventional therapies such as atypical antipsychotics are discussed.....
The evidence base for emerging therapies including citalopram and pimavanserin in relation to conventional therapies such as atypical …
Atypical antipsychotic use and mortality risk in Parkinson disease.
Pham Nguyen TP, Thibault D, Hamedani AG, Weintraub D, Willis AW. Pham Nguyen TP, et al. Parkinsonism Relat Disord. 2022 Oct;103:17-22. doi: 10.1016/j.parkreldis.2022.08.013. Epub 2022 Aug 19. Parkinsonism Relat Disord. 2022. PMID: 36027858 Free PMC article.
INTRODUCTION: Dopamine receptor blocking atypical antipsychotic (DRB-AAP) use has previously been associated with increased adverse effects and mortality risk among persons with Parkinson disease (PD). ...CONCLUSION: Mortality risk among PD patients using AAP …
INTRODUCTION: Dopamine receptor blocking atypical antipsychotic (DRB-AAP) use has previously been associated with increased ad …
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
Kurhan F, Akın M. Kurhan F, et al. Curr Alzheimer Res. 2023;20(6):403-408. doi: 10.2174/1567205020666230825124922. Curr Alzheimer Res. 2023. PMID: 37641988
Alzheimer's disease (AD) ranks first among the causes of dementia worldwide. ...There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). Ho …
Alzheimer's disease (AD) ranks first among the causes of dementia worldwide. ...There is no treatment approved by the U …
Cholinesterase Inhibitors for Delusions and Hallucinations in Alzheimer Disease and Parkinson Disease: Questionably Significant Benefits.
Andrade C. Andrade C. J Clin Psychiatry. 2023 Jul 31;84(4):23f15009. doi: 10.4088/JCP.23f15009. J Clin Psychiatry. 2023. PMID: 37530610 Free article.
Delusions and hallucinations are common in Alzheimer disease (AD) and Parkinson disease (PD), especially in the later stages of illness. ...Therefore, if psychotic symptoms persist for 24 weeks despite optimally dosed ChEI treatment, and if behavioral and psy …
Delusions and hallucinations are common in Alzheimer disease (AD) and Parkinson disease (PD), especially in the later s …
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M; Consortium on DLB. McKeith IG, et al. Neurology. 2005 Dec 27;65(12):1863-72. doi: 10.1212/01.wnl.0000187889.17253.b1. Epub 2005 Oct 19. Neurology. 2005. PMID: 16237129 Review.
The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. ...There is limited evidence about specific interventions but available data suggest on …
The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that …
316 results